Cancer screening recommendations: An international comparison of high income countries

Mark H. Ebell, Thuy Nhu Thai, Kyle J. Royalty

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Background: Recommendations regarding cancer screening vary from country to country, and may also vary within countries depending on the organization making the recommendations. The goal of this study was to summarize the cancer screening recommendations from the 21 countries with the highest per capita spending on healthcare. Main body: Cancer screening guidelines were identified for each country based on a review of the medical literature, internet searches, and contact with key informants in most countries. The highest level recommendation was identified for each country, in the order of national recommendation, cancer society recommendation, or medical specialty society recommendation. Breast cancer screening recommendations were generally consistent across countries, most commonly recommending mammography biennially from ages 50 to 69 or 70 years. In the USA, specialty societies generally offered more intensive screening recommendations. All countries also recommend cervical cancer screening, although there is some heterogeneity regarding the test (cytology or HPV or both) and the age of initiation and screening interval. Most countries recommend colorectal cancer screening using fecal immunochemical (FIT) testing, while only seven countries recommend general or selective screening for prostate cancer, and a similar number explicitly recommend against screening for prostate cancer. Screening for lung and skin cancer is only recommended by a few countries. Greater per capita healthcare expenditures are not associated with greater screening intensity, with the possible exception of prostate cancer. Conclusions: Guidelines for cancer screening differ between countries, with areas of commonality but also clear differences. Recommendations have important commonalities for well-established cancer screening programs such as breast and cervical cancer, with greater variation between countries regarding prostate, colorectal, lung, and skin cancer screening. Ideally, recommendations should be made by a professionally diverse, independent panel of experts that make evidence-based recommendations regarding screening based on the benefits, harms, and available resources in that country's context.

Original languageEnglish (US)
Article number7
JournalPublic Health Reviews
Volume39
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Skin Neoplasms
Uterine Cervical Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Guidelines
Breast Neoplasms
Delivery of Health Care
Medical Societies
Mammography
Health Expenditures
Internet
Cell Biology
Medicine
Organizations

Keywords

  • Breast cancer
  • Cancer screening
  • Cervical cancer
  • Colorectal cancer
  • Healthcare economics
  • Lung cancer
  • Overdiagnosis
  • Prostate cancer
  • Skin cancer

ASJC Scopus subject areas

  • Community and Home Care
  • Public Health, Environmental and Occupational Health

Cite this

Cancer screening recommendations : An international comparison of high income countries. / Ebell, Mark H.; Thai, Thuy Nhu; Royalty, Kyle J.

In: Public Health Reviews, Vol. 39, No. 1, 7, 01.01.2018.

Research output: Contribution to journalReview article

Ebell, Mark H. ; Thai, Thuy Nhu ; Royalty, Kyle J. / Cancer screening recommendations : An international comparison of high income countries. In: Public Health Reviews. 2018 ; Vol. 39, No. 1.
@article{3edf55156b0e412786bdeca1531ccfed,
title = "Cancer screening recommendations: An international comparison of high income countries",
abstract = "Background: Recommendations regarding cancer screening vary from country to country, and may also vary within countries depending on the organization making the recommendations. The goal of this study was to summarize the cancer screening recommendations from the 21 countries with the highest per capita spending on healthcare. Main body: Cancer screening guidelines were identified for each country based on a review of the medical literature, internet searches, and contact with key informants in most countries. The highest level recommendation was identified for each country, in the order of national recommendation, cancer society recommendation, or medical specialty society recommendation. Breast cancer screening recommendations were generally consistent across countries, most commonly recommending mammography biennially from ages 50 to 69 or 70 years. In the USA, specialty societies generally offered more intensive screening recommendations. All countries also recommend cervical cancer screening, although there is some heterogeneity regarding the test (cytology or HPV or both) and the age of initiation and screening interval. Most countries recommend colorectal cancer screening using fecal immunochemical (FIT) testing, while only seven countries recommend general or selective screening for prostate cancer, and a similar number explicitly recommend against screening for prostate cancer. Screening for lung and skin cancer is only recommended by a few countries. Greater per capita healthcare expenditures are not associated with greater screening intensity, with the possible exception of prostate cancer. Conclusions: Guidelines for cancer screening differ between countries, with areas of commonality but also clear differences. Recommendations have important commonalities for well-established cancer screening programs such as breast and cervical cancer, with greater variation between countries regarding prostate, colorectal, lung, and skin cancer screening. Ideally, recommendations should be made by a professionally diverse, independent panel of experts that make evidence-based recommendations regarding screening based on the benefits, harms, and available resources in that country's context.",
keywords = "Breast cancer, Cancer screening, Cervical cancer, Colorectal cancer, Healthcare economics, Lung cancer, Overdiagnosis, Prostate cancer, Skin cancer",
author = "Ebell, {Mark H.} and Thai, {Thuy Nhu} and Royalty, {Kyle J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1186/s40985-018-0080-0",
language = "English (US)",
volume = "39",
journal = "Public Health Reviews",
issn = "0301-0422",
publisher = "EHESP Presses",
number = "1",

}

TY - JOUR

T1 - Cancer screening recommendations

T2 - An international comparison of high income countries

AU - Ebell, Mark H.

AU - Thai, Thuy Nhu

AU - Royalty, Kyle J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Recommendations regarding cancer screening vary from country to country, and may also vary within countries depending on the organization making the recommendations. The goal of this study was to summarize the cancer screening recommendations from the 21 countries with the highest per capita spending on healthcare. Main body: Cancer screening guidelines were identified for each country based on a review of the medical literature, internet searches, and contact with key informants in most countries. The highest level recommendation was identified for each country, in the order of national recommendation, cancer society recommendation, or medical specialty society recommendation. Breast cancer screening recommendations were generally consistent across countries, most commonly recommending mammography biennially from ages 50 to 69 or 70 years. In the USA, specialty societies generally offered more intensive screening recommendations. All countries also recommend cervical cancer screening, although there is some heterogeneity regarding the test (cytology or HPV or both) and the age of initiation and screening interval. Most countries recommend colorectal cancer screening using fecal immunochemical (FIT) testing, while only seven countries recommend general or selective screening for prostate cancer, and a similar number explicitly recommend against screening for prostate cancer. Screening for lung and skin cancer is only recommended by a few countries. Greater per capita healthcare expenditures are not associated with greater screening intensity, with the possible exception of prostate cancer. Conclusions: Guidelines for cancer screening differ between countries, with areas of commonality but also clear differences. Recommendations have important commonalities for well-established cancer screening programs such as breast and cervical cancer, with greater variation between countries regarding prostate, colorectal, lung, and skin cancer screening. Ideally, recommendations should be made by a professionally diverse, independent panel of experts that make evidence-based recommendations regarding screening based on the benefits, harms, and available resources in that country's context.

AB - Background: Recommendations regarding cancer screening vary from country to country, and may also vary within countries depending on the organization making the recommendations. The goal of this study was to summarize the cancer screening recommendations from the 21 countries with the highest per capita spending on healthcare. Main body: Cancer screening guidelines were identified for each country based on a review of the medical literature, internet searches, and contact with key informants in most countries. The highest level recommendation was identified for each country, in the order of national recommendation, cancer society recommendation, or medical specialty society recommendation. Breast cancer screening recommendations were generally consistent across countries, most commonly recommending mammography biennially from ages 50 to 69 or 70 years. In the USA, specialty societies generally offered more intensive screening recommendations. All countries also recommend cervical cancer screening, although there is some heterogeneity regarding the test (cytology or HPV or both) and the age of initiation and screening interval. Most countries recommend colorectal cancer screening using fecal immunochemical (FIT) testing, while only seven countries recommend general or selective screening for prostate cancer, and a similar number explicitly recommend against screening for prostate cancer. Screening for lung and skin cancer is only recommended by a few countries. Greater per capita healthcare expenditures are not associated with greater screening intensity, with the possible exception of prostate cancer. Conclusions: Guidelines for cancer screening differ between countries, with areas of commonality but also clear differences. Recommendations have important commonalities for well-established cancer screening programs such as breast and cervical cancer, with greater variation between countries regarding prostate, colorectal, lung, and skin cancer screening. Ideally, recommendations should be made by a professionally diverse, independent panel of experts that make evidence-based recommendations regarding screening based on the benefits, harms, and available resources in that country's context.

KW - Breast cancer

KW - Cancer screening

KW - Cervical cancer

KW - Colorectal cancer

KW - Healthcare economics

KW - Lung cancer

KW - Overdiagnosis

KW - Prostate cancer

KW - Skin cancer

UR - http://www.scopus.com/inward/record.url?scp=85049384414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049384414&partnerID=8YFLogxK

U2 - 10.1186/s40985-018-0080-0

DO - 10.1186/s40985-018-0080-0

M3 - Review article

AN - SCOPUS:85049384414

VL - 39

JO - Public Health Reviews

JF - Public Health Reviews

SN - 0301-0422

IS - 1

M1 - 7

ER -